These four ASX healthcare shares are bucking the trend today with strong share price gains following the release of their latest financial reports.
As earnings season continues, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.087%, while the S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.34%.
Let's review these results.
4 ASX healthcare shares ripping up the charts today
Starpharma Holdings Ltd (ASX: SPL)
ASX healthcare share Starpharma rose to an intraday high of 16 cents, up 14.3%, after the ASX biotech company released its preliminary full-year FY23 results. Starpharma revealed a 14% decline in revenue to $4.2M and a reported loss of $15.6 million, which was a 3% improvement on FY22. The company said its loss was due to research and product development expenses of $11.239 million.
Telix Pharmaceuticals Ltd (ASX: TLX)
ASX healthcare share Telix Pharmaceuticals is also rising high today, up 10.8% at its intraday peak of $10.85. The radiation therapy biotech released its half-year FY23 results today. Telix reported revenue of $220.8 million, up from just $24 million in 1H FY22. The company said the revenue surge was largely due to growing sales of its prostate cancer imaging agent, Illuccix, which was launched in the United States in April 2022. At the bottom line was a net loss after tax of $14.3 million.
Pacific Smiles Group Ltd (ASX: PSQ)
Pacific Smiles shares rose to an intraday high of $1.37, up 8.7%, after the dental services network released its full-year FY23 results. Group revenue came in at $165.3 million, up 18.5% on FY22. Underlying earnings before interest, taxes, depreciation, and amortisation (EBITDA) was $24.1 million, up 113.9%. The underlying net profit after tax (NPAT) was $4.5 million, up from a net loss of $3.2 million in FY22. The ASX healthcare share will pay a fully franked final dividend of 2.27 cents per share (cps). The total annual dividend is 2.62 cps, representing a payout ratio of 100% of underlying NPAT.
SDI Ltd (ASX: SDI)
SDI shares rose to an intraday high of 89 cents, up 4.7%, after the dental materials developer and manufacturer revealed record sales of $107.9 million in its full-year FY23 report. Sales went up 13.3% on FY22, and EBITDA increased by 9.6% to $16.2 million. The product margin improved by 100 basis points to 56.8% following price increases and some lower logistics costs. Earnings per share (EPS) was down 19 cents to 5.94 cps. The ASX healthcare share will pay a fully franked final dividend of 1.75 cps.
